Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease

(2012) A. B. Chapman et al.   Clinical Journal of the American Society of Nephrology

CARCINOID TUMOUR MANAGEMENT IN HAEMODIALYSIS: A CASE REPORT

(2012) Michael T Burke et al.   NEPHROLOGY

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

(2011) Melissa Chrispijn et al.   Trials

Reducing Polycystic Liver Volume in ADPKD: Effects of Somatostatin Analogue Octreotide

(2010) A. Caroli et al.   Clinical Journal of the American Society of Nephrology

Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease

(2010) Ramón Peces et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease

(2010) M. C. Hogan et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient

(2010) M. Adabala et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Effect of octreotide on polycystic liver volume

(2009) Loes van Keimpema et al.   LIVER INTERNATIONAL

Somatostatin analogues reduce liver volume in polycystic liver disease

(2008) L van Keimpema et al.   GUT